S16 Ep47: The Intricacies of Approved Therapies Pose Questions for CLL Management: With Mazyar Shadman, MD, MPH
In today’s episode Mazyar Shadman, MD, MPH, discussed results from a post hoc indirect comparison that evaluated zanubrutinib (Brukinsa) from phase 3 SEQUOIA trial (NCT03336333) compared with acalabrutinib (Calquence) plus venetoclax (Venclexta) from the phase 3 AMPLIFY trial (NCT03836261) in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Shadman is a professor in the Clinical Research Division, medical director of Cellular Immunotherapy, and the Innovators Network Endowed Chair at Fred Hutchinson Cancer Center in Seattle, Washington.
In our exclusive interview, Dr…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.